Optilume™ BPH Prostatic Drug Coated Balloon Dilation Catheter
Status:
Active, not recruiting
Trial end date:
2024-03-30
Target enrollment:
Participant gender:
Summary
A prospective, non-randomized study. The subjects will be enrolled and treated with the
Optilume BPH Prostatic DCB Dilation Catheter System at up to 8 clinical sites. The
post-treatment follow-up visit can be up to 5 years.
The objective of the study is to evaluate the safety and efficacy of the Optilume™ BPH
Prostatic Drug Coated Balloon Dilation Catheter System in the treatment of BPH.